uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
Company profile
Ticker
QURE
Exchange
Website
CEO
Matthew C. Kapusta
Employees
Location
Fiscal year end
Industry (SIC)
Former names
uniQure B.V.
SEC CIK
Corporate docs
Subsidiaries
uniQure biopharma B.V. • uniQure IP B.V. • uniQure Inc. • uniQure France SAS • Corlieve Therapeutics AG ...
QURE stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Departure of Directors or Certain Officers
12 Apr 24
S-8
Registration of securities for employees
28 Feb 24
8-K
Results of Operations and Financial Condition
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Gene Therapy for the Treatment of Huntington’s Disease
19 Dec 23
S-8
Registration of securities for employees
8 Dec 23
8-K
Departure of Directors or Certain Officers
17 Nov 23
Transcripts
Latest ownership filings
4
Matthew C Kapusta
5 Mar 24
4
CHRISTIAN KLEMT
5 Mar 24
4
Walid Abi-Saab
5 Mar 24
4
PIERRE CALOZ
5 Mar 24
4
Jeannette Potts
5 Mar 24
4
PIERRE CALOZ
28 Feb 24
4
CHRISTIAN KLEMT
28 Feb 24
4
Matthew C Kapusta
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 232.64 mm | 232.64 mm | 232.64 mm | 232.64 mm | 232.64 mm | 232.64 mm |
Cash burn (monthly) | 94.71 mm | 17.57 mm | 29.88 mm | 17.49 mm | (no burn) | 12.59 mm |
Cash used (since last report) | 651.73 mm | 120.87 mm | 205.61 mm | 120.35 mm | n/a | 86.63 mm |
Cash remaining | -419.09 mm | 111.77 mm | 27.03 mm | 112.28 mm | n/a | 146.01 mm |
Runway (months of cash) | -4.4 | 6.4 | 0.9 | 6.4 | n/a | 11.6 |
Institutional ownership, Q3 2023
74.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 159 |
Opened positions | 32 |
Closed positions | 52 |
Increased positions | 59 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 230.36 bn |
Total shares | 35.40 mm |
Total puts | 319.40 k |
Total calls | 708.60 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
STT State Street | 3.45 mm | $23.15 bn |
Nantahala Capital Management | 3.02 mm | $20.29 bn |
MS Morgan Stanley | 2.68 mm | $17.99 bn |
Orbimed Advisors | 2.06 mm | $13.85 bn |
BLK Blackrock | 1.73 mm | $11.62 bn |
683 Capital Management | 1.58 mm | $10.57 bn |
International Biotechnology Trust | 1.24 mm | $8.33 bn |
Pictet Asset Management Holding | 1.00 mm | $6.73 bn |
BCS Barclays | 989.56 k | $6.64 mm |
Vanguard | 953.44 k | $6.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Matthew C Kapusta | Ordinary Shares | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 590,839 |
1 Mar 24 | Matthew C Kapusta | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 5.59 | 259,500 | 1.45 mm | 259,500 |
1 Mar 24 | Christian Klemt | Ordinary Shares | Grant | Acquire A | No | No | 0 | 49,500 | 0.00 | 166,448 |
1 Mar 24 | Christian Klemt | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 5.59 | 85,500 | 477.95 k | 85,500 |
1 Mar 24 | Walid Abi-Saab | Ordinary Shares | Grant | Acquire A | No | No | 0 | 49,500 | 0.00 | 116,700 |
1 Mar 24 | Walid Abi-Saab | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 5.59 | 85,500 | 477.95 k | 85,500 |
1 Mar 24 | Pierre Caloz | Ordinary Shares | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 118,643 |
1 Mar 24 | Pierre Caloz | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 5.59 | 57,000 | 318.63 k | 57,000 |
1 Mar 24 | Jeannette Potts | Ordinary Shares | Grant | Acquire A | No | No | 0 | 49,500 | 0.00 | 96,600 |
1 Mar 24 | Jeannette Potts | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 5.59 | 85,500 | 477.95 k | 85,500 |
News
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
4 Mar 24
Mizuho Maintains Neutral on uniQure, Lowers Price Target to $7
4 Mar 24
HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $25
1 Mar 24
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
Goldman Sachs Downgrades uniQure to Neutral, Lowers Price Target to $8
29 Feb 24